30 July - Tuesday

Preliminary program - subject to change.

08:00 - 09:00

Plenary Lecture 2

09:00 - 09:30

Refreshment Break with Exhibitors and Posters

09:30 - 11:30

Concurrent Sessions: Symposia 5 and 6

Symposium 5: Disease Effect on Transporter Regulation and Function
Co-Chairs: Kathy Giacomini, University of California San Francisco, San Francisco, California, USA and Raymond Evers, Merck & Co. Inc., Kenilworth, New Jersey, USA

Proteomics Based Studies of Disease Effects on the Brain Barrier Transporters
Tetsuya Terasaki, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai. Japan

SLC16A11: From Human Genetics to Novel Mechanisms Underlying Type 2 Diabetes
Eitan Hoch, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

Transporters in Polycystic Kidney Disease
Kim Brouwer, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA

Liver Transporter Activity in Patients with Renal Disease
Aubrey Stoch, Merck & Co. Inc., Rahway, New Jersey, USA

Symposium 6: Advances in the Study of Drug Metabolism

Co-Chairs: Iain Martin, Merck & Co. Inc., Boston, Massachusetts, USA and Mitchell E. Taub, Boehringer Ingelheim, Ridgefield, Connecticut, USA

Predicting Routes, Sites, and Products of Metabolism
Matt Segall, Optibrium, Cambridge, United Kingdom

Substrate Recognition by Cytochrome P450s
Emily Scott, University of Michigan, Ann Arbor, Michigan, USA

Application of in silico DMPK in Drug Discovery and Development
Fabio Brocatelli, Genentech, South San Francisco, California, USA

Biosynthesis of Drug Candidates and Metabolites
Griff Humphreys, Aranmore Pharma Consultants, Lawrenceville, New Jersey, USA

11:30 - 14:00

Lunch with Exhibitors and Poster Presentations

14:00 - 16:00

Concurrent Sessions: Symposia 7 and 8

Symposium 7: Driving Asia-Inclusive Global Drug Development through Translational Science and Clinical Pharmacology: Towards Enhanced Benefit-Risk and Decreased Access Lag
Co-Chairs: Lei Zhang, Silver Spring, Maryland, USA and Karthik Venkatakrishnan, Takeda Pharmaceuticals, USA

Enabling Asia-Inclusive Global Drug Development through Quantitative and Translational Science
Karthik Venkatakrishnan, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA

Impact of Racial/Ethnic Differences in Drug Response
Anuradha Ramamoorthy, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

Prediction of Differences in Pharmacokinetics between Chinese, Japanese, and Caucasian Populations - An Update
Geoffrey Tucker, University of Sheffield, Sheffield, United Kingdom

Lecture Title to be Confirmed
Kathy Giacomini, University of California San Francisco, San Francisco, California, USA

Symposium 8: State-of-the-Art Approaches in DMET Biomarker Research: Path from Discovery to Validation
Co-Chairs: Xiaoyan Chu, Merck & Co. Inc., Boston, Massachusetts, USA and Hiroyuki Kusuhara, University of Tokyo, Tokyo, Japan

Biomarkers for in vivo Assessment of Transporter Function
Martin F. Fromm, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Erlangen, Germany

Mechanistic Models for Coproporphyrin I and Creatinine as Endogenous Biomarkers for Transporter Drug-drug Interactions
Aleksandra Galetin, University of Manchester, Manchester, United Kingdom

Knockout Mice, Transcriptomics and Metabolomics Approach for Discovery of Renal Drug Transporters
Sanjay Nigam, University of California San Diego, San Diego, California, USA

State-of-the-Art Approaches in DMET Biomarker Research: Path from Discovery to Validation
Bhagwat Prasad, University of Washington, Seattle, Washington, USA

16:30 - 17:30

ISSX Focus Group Meetings

Industry-Sponsored Symposia

17:30 - 18:30

Poster Viewing in Exhibit Hall

18:30 - 19:30